| Autor: |
Silvestris N; IRCCS Istituto Tumori 'Giovanni Paolo II', 70124, Bari, Italy. n.silvestris@oncologico.bari.it.; Department of Biomedical Sciences and Human Oncology, University of Bari 'Aldo Moro', Bari, Italy. n.silvestris@oncologico.bari.it., Apolone G; Scientific Directorate, Fondazione IRCCS Istituto Tumori di Milano, Milan, Italy., Botti G; Scientific Directorate, Istituto Nazionale Tumori, 'Fondazione G. Pascale' - IRCCS Naples, Naples, Italy., Ciliberto G; Scientific Directorate, IRCCS Regina Elena National Cancer Institute, Rome, Italy., Costantini M; Scientific Directorate, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy., De Paoli P; Alliance Against Cancer, Rome, Italy., Franceschi S; Scientific Directorate, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy., Opocher G; Scientific Directorate, Veneto Institute of Oncology, IOV-IRCCS, Padova, Italy., Paradiso A; Scientific Directorate IRCCS Istituto Tumori 'Giovanni Paolo II' of Bari, Bari, Italy., Pronzato P; Department of Oncology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy., Sgambato A; Scientific Directorate IRCCS CROB Rionero in Vulture, Rionero in Vulture, Italy., De Maria R; Alliance Against Cancer, Rome, Italy.; Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy. |
| Abstrakt: |
If we focus our attention on seven main features of COVID-19 infection (heterogeneity, fragility, lack of effective treatments and vaccines, "miraculous cures", psychological suffering, deprivation, and globalization), we may establish parallelism with the challenges faced in the steep road to the understanding and treatment of neoplastic diseases. How the similarities between these two conditions can help us cope with the emergency effort represented by the management of cancer patients in the COVID-19 era, today and in the future? In a manner similar to the Cancer Moonshot initiative in the United States, we can hypothesize a multinational moonshot project towards the management of cancer patients during COVID-19 pandemic. In particular, we believe that the main road to elaborate meaningful scientific evidence is represented by the collection of all the data on COVID-19 and cancer comorbidity that are and will become available in cancer centers, coupled with the design of large clinical studies. To address this goal, it is essential to identify the entity that can produce this scientific evidences and the potentially most successful research strategy to undertake. The largest Italian organization for cancer research, Alliance Against Cancer (Alleanza Contro il Cancro, ACC), is called to play a scientific leadership in addressing these challenges, which requires the coordination of oncology teams at regional, national, and international levels. To fulfill this commitment, ACC will create a liaison with health government agencies in order to develop "dynamic" indications able to fight such an unpredictable pandemic. |
